Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Battey skin test (BST) antigen is a diagnostic biologic reagent derived from *Mycobacterium intracellulare* (historically known as the Battey bacillus). It is utilized in the differential diagnosis of latent tuberculosis infection (LTBI) to identify cross-reactivity caused by non-tuberculous mycobacteria (NTM). When administered intradermally via the Mantoux method, the antigen elicits a delayed-type hypersensitivity (DTH) response in individuals previously sensitized to the *Mycobacterium avium* complex (MAC). By comparing the induration size of a BST reaction to that of a standard Tuberculin Skin Test (TST), clinicians can better distinguish between true *Mycobacterium tuberculosis* infection and false-positive TST results resulting from environmental mycobacterial exposure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Battey skin test antigen.